{"entity":{"id":"hoff-paulo","kind":"person","name":"Paulo Hoff","aka":[],"tldr":"Brazil's most prominent GI oncologist, a former MD Anderson faculty member who built oncology programmes at Sírio-Libanês and ICESP.","summary":"Paulo Hoff is a medical oncologist specialising in gastrointestinal cancer and a leader of Brazilian oncology through Hospital Sírio-Libanês, the University of São Paulo and Oncologia D'Or. A former MD Anderson faculty member, he led research on capecitabine and colorectal cancer there before returning to Brazil, where he directed the oncology centre at Sírio-Libanês and the São Paulo State Cancer Institute and later led Oncologia D'Or. His publications include the trial comparing oral capecitabine with intravenous fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. He is Brazil's most prominent gastrointestinal oncologist, with interests in colorectal cancer, clinical trials and oncology leadership.","asOf":"2026-09-08","links":[{"label":"Hospital Sírio-Libanês","url":"https://www.hospitalsiriolibanes.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hoff%20PM%5BAuthor%5D%20colorectal%20capecitabine"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["folfox"],"companies":[],"institutions":["sirio-libanes"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist; gastrointestinal oncology; Brazilian oncology leadership (Sírio-Libanês, USP, Oncologia D'Or)","institutionId":"sirio-libanes","specialisms":["Colorectal cancer","Gastrointestinal oncology","Clinical trials","Oncology leadership"],"profiles":[{"label":"Hospital Sírio-Libanês","url":"https://www.hospitalsiriolibanes.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hoff%20PM%5BAuthor%5D%20colorectal%20capecitabine"}],"papers":[{"title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in patients with metastatic colorectal cancer","journal":"Journal of Clinical Oncology","year":2001,"doi":"10.1200/JCO.2001.19.8.2282"}]},"route":"/people/hoff-paulo/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"institution":[{"id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","route":"/institutions/anvisa/"},{"id":"sirio-libanes","kind":"institution","name":"Hospital Sírio-Libanês","route":"/institutions/sirio-libanes/"}]}}